One of the upstream regulatory molecules of CPT1 in breast cancers with high metastasis as a therapeutic challenge is ACSL4 (long-chain acyl-coenzyme A synthase 4), which affects the FAO process and hinders therapeutic efficacy by promoting its expression [62]. This evidence concerns the gene CPT2 and breast cancer.